Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;12(3):204-210.
doi: 10.4103/1735-5362.207201.

Comparative effects of chronic administrations of gabapentin, pregabalin and baclofen on rat memory using object recognition test

Affiliations

Comparative effects of chronic administrations of gabapentin, pregabalin and baclofen on rat memory using object recognition test

Asma Salimzade et al. Res Pharm Sci. 2017 Jun.

Abstract

Memory impairment is one of the greatest concerns when it comes to long-term CNS-affecting drug administration. Drugs like gabapentin, pregabalin and baclofen are administered in a long-term period in conditions such as epilepsy, neuropathic pain, spasticity associated with spinal cord injury or multiple sclerosis. Despite their wide spread use, few data are available on the effects of these drugs on cognitive functions, such as learning memory. In the present study, the effects of long-term administration of gabapentin, pregabalin and baclofen on memory were investigated in a comparative manner. Male Wistar rats received intraperitoneal (i.p.) injection of gabapentin (30 mg/kg), pregabalin (30 mg/kg), baclofen (3 mg/kg), combination of gabapentin/baclofen (30/3 mg/kg) and combination of pregabalin/baclofen (30/3 mg/kg) once a day for 3 weeks respective to their groups. After the end of treatments, rat memories were assessed using the object-recognition task. The discrimination and recognition indices (RI and DI) in the T2 trials were used as the memory indicating factors. The results showed that daily i.p. administrations of pregabalin but not gabapentin or baclofen significantly decreased DI and RI compared to saline group. In combination groups, either gabapentin or pregabalin impaired discrimination between new and familiar objects. Our findings suggested that pregabalin alone or in combination with baclofen significantly caused cognitive deficits.

Keywords: Baclofen; Chronic; Gabapentin; Memory; Object recognition task; Pregabalin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Comparative effects of gabapentin, pregabalin, baclofen and the combinations on the discrimination index. Gabapentin (30 mg/kg), pregabalin (30 mg/kg), baclofen (3 mg/kg), gabapentin/baclofen (30/3 mg/kg) and pregabalin/baclofen (30/3 mg/kg) were administered i.p. for 21 consecutive days, from 8-10 A.M every day. Animal performance was evaluated 24 h after the last injection. Data are expressed as means ± SEM. *P < 0.05 and ***P < 0.001 vs control group, #P < 0.05 gabapentin vs pregabalin group. ##P < 0.01 gabapentin vs gabapentin/baclofen.
Fig. 2
Fig. 2
Comparative effects of gabapentin, pregabalin, baclofen and the combinations on the recognition index. Gabapentin (30 mg/kg), pregabalin (30 mg/kg) and baclofen (3 mg/kg), gabapentin/baclofen (30/3 mg/kg) and pregabalin/baclofen (30/3 mg/kg) were administered i.p. for 21 consecutive days, from 8-10 A.M every day. Animal performance was evaluated 24 h after the last injection. Data are expressed as means ± SEM. ***P < 0.001 vs control group, #P < 0.05 pregabalin and the combination of gabapentin/baclofen vs gabapentin group.

Similar articles

Cited by

  • Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
    Lam M, Chen CY, Ge T, Xia Y, Hill DW, Trampush JW, Yu J, Knowles E, Davies G, Stahl EA, Huckins L, Liewald DC, Djurovic S, Melle I, Christoforou A, Reinvang I, DeRosse P, Lundervold AJ, Steen VM, Espeseth T, Räikkönen K, Widen E, Palotie A, Eriksson JG, Giegling I, Konte B, Hartmann AM, Roussos P, Giakoumaki S, Burdick KE, Payton A, Ollier W, Chiba-Falek O, Koltai DC, Need AC, Cirulli ET, Voineskos AN, Stefanis NC, Avramopoulos D, Hatzimanolis A, Smyrnis N, Bilder RM, Freimer NB, Cannon TD, London E, Poldrack RA, Sabb FW, Congdon E, Conley ED, Scult MA, Dickinson D, Straub RE, Donohoe G, Morris D, Corvin A, Gill M, Hariri AR, Weinberger DR, Pendleton N, Bitsios P, Rujescu D, Lahti J, Le Hellard S, Keller MC, Andreassen OA, Deary IJ, Glahn DC, Huang H, Liu C, Malhotra AK, Lencz T. Lam M, et al. Neuropsychopharmacology. 2021 Sep;46(10):1788-1801. doi: 10.1038/s41386-021-01023-4. Epub 2021 May 25. Neuropsychopharmacology. 2021. PMID: 34035472 Free PMC article.
  • Spinal cord injury-induced cognitive impairment: a narrative review.
    Alcántar-Garibay OV, Incontri-Abraham D, Ibarra A. Alcántar-Garibay OV, et al. Neural Regen Res. 2022 Dec;17(12):2649-2654. doi: 10.4103/1673-5374.339475. Neural Regen Res. 2022. PMID: 35662196 Free PMC article. Review.
  • Anti-inflammatory effect of pregabalin on acetic acid-induced colitis in the rats.
    Motavallian A, Zamani E, Bouzari S, Rezaeyan F, Karimian P, Evazalipour M. Motavallian A, et al. Res Pharm Sci. 2021 Nov 11;17(1):35-42. doi: 10.4103/1735-5362.329924. eCollection 2022 Feb. Res Pharm Sci. 2021. PMID: 34909042 Free PMC article.
  • Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study.
    Weiner JK, Smith T, Hoy CK, Sarosh C, Madison JA, Ambati A, Tambralli A, Peters N, Packel C, Gockman K, Zuo Y, Briceño EM, Nagaraja V, Knight JS. Weiner JK, et al. ACR Open Rheumatol. 2023 Jan;5(1):28-37. doi: 10.1002/acr2.11512. Epub 2022 Dec 2. ACR Open Rheumatol. 2023. PMID: 36461647 Free PMC article.
  • Activation of the RMTg Nucleus by Chemogenetic Techniques Alleviates the Learning and Memory Impairment in APP/PS1 Mice.
    Zheng L, Wang Z, Liu Y, Zhao J, Huang S. Zheng L, et al. Neuropsychiatr Dis Treat. 2022 Dec 20;18:2957-2965. doi: 10.2147/NDT.S388832. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36573138 Free PMC article.

References

    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurol. 2015;14(2):162–173. - PMC - PubMed
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–2205. - PubMed
    1. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6(Suppl A):61–68. - PubMed
    1. Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12(6):804–813. - PubMed
    1. Ivanhoe CB, Reistetter TA. Spasticity: the misunderstood part of the upper motor neuron syndrome. Am J Phys Med Rehabil. 2004;83(10):S3–S9. - PubMed